Pay in 4 interest-free payments of $7.28 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Prescribers managing CKD patients today should default to Saxenda or semaglutide (which has CKD-specific renal data from FLOW, NCT03819153) rather than waiting for retatrutide's CKD profile to be established
Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin
Safety results show which side effects occurred and how often participants stopped treatment
c k hng dn trc khi dng
Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial
